Disclaimer

The alfapump® system is currently not approved in Canada for commercial use. DSR® therapy is still in development and is currently not approved in the United States or Canada. Any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. Sequana Medical makes no claims of safety or effectiveness of the DSR® therapy in the U.S. or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Day

April 14, 2025
PERSBERICHT NIET-GEREGLEMENTEERDE INFORMATIE 14 april 2025, 07:00 am CET New Technology Add-on Payment (NTAP) opgenomen in de voorgestelde regelgeving voor het fiscale jaar 2026, zal naar verwachting in augustus 2025 worden afgerond en op 1 oktober 2025 van kracht worden Lanceringscentra op schema om training eind april af te ronden De commerciële lancering van alfapump®...
Read More

PERSBERICHTEN

INSCHRIJVEN OP ONZE PERSBERICHTEN